Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12192.158 | 1.0043 | 1.0129 | 0.6680 | |
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12192.158 | 0.8936 | 0.6901 | 0.6680 | |
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12192.158 | 0.8931 | 0.6886 | 0.6680 | |
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12192.158 | 0.7189 | 0.2204 | 0.6680 | |
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12192.158 | 0.2010 | -0.8189 | 0.6680 | |
| HCC2185 | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12192.158 | 0.0119 | -0.9974 | 0.6680 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 11850.158 | 0.9536 | 0.9527 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 11850.158 | 1.0076 | 1.0076 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 11850.158 | 0.9180 | 0.9156 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 11850.158 | 1.0068 | 1.0068 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 11850.158 | 0.8755 | 0.8705 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 11850.158 | 0.8533 | 0.8464 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 11850.158 | 0.5216 | 0.4410 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 11850.158 | 0.0129 | -0.7760 | 1.9855 | |
| HCC38 | TNBC | Basal B | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 11850.158 | 0.0075 | -0.8302 | 1.9855 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12400.165 | 1.0022 | 1.0034 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.000853 | uM | 12400.165 | 0.9538 | 0.9288 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.00427 | uM | 12400.165 | 0.9426 | 0.9114 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.0213 | uM | 12400.165 | 0.8424 | 0.7537 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12400.165 | 0.7710 | 0.6389 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 0.533 | uM | 12400.165 | 0.7251 | 0.5636 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 2.67 | uM | 12400.165 | 0.4328 | 0.0531 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12400.165 | 0.0164 | -0.9140 | 1.3057 | |
| HCC70 | TNBC | Basal A | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12400.165 | 0.0096 | -0.9431 | 1.3057 | |
| LY2 | HR+ | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.000171 | uM | 12319.165 | 0.8891 | 0.7581 | 0.9117 |